Adma Biologics, Inc. (ADMA) — SEC Filings
Adma Biologics, Inc. (ADMA) — 44 SEC filings. Latest: 8-K (May 4, 2026). Includes 23 8-K, 6 10-Q, 6 SC 13G.
View Adma Biologics, Inc. on SEC EDGAR
Overview
Adma Biologics, Inc. (ADMA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 27, 2026: ADMA Biologics, Inc. filed an 8-K on March 27, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The filing includes various exhibits, such as an iXBRL 8-K document, graphic images, and XBRL data files, but does not contain specific financi
Sentiment Summary
Across 44 filings, the sentiment breakdown is: 43 neutral, 1 mixed. The dominant filing sentiment for Adma Biologics, Inc. is neutral.
Filing Type Overview
Adma Biologics, Inc. (ADMA) has filed 23 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 5 SC 13G/A, 6 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (44)
Risk Profile
Risk Assessment: Of ADMA's 30 recent filings, 0 were flagged as high-risk, 9 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $371.01M |
| Net Income | $97.55M |
| EPS | $0.41 |
| Cash Position | $61.39M |
| Operating Margin | 34.7% |
| Total Assets | $568.69M |
| Total Debt | $72.43M |
Key Executives
- Dr. David L. H. Chung
- Mr. David M. S. Chung
- Adam L. Havey
- Michael A. Farrell
- Maria T. Palombini, M.D.
Industry Context
ADMA Biologics operates in the biopharmaceutical sector, focusing on plasma-derived biologics. The industry is characterized by high R&D costs, stringent regulatory oversight (FDA), and a competitive landscape for sourcing plasma and commercializing specialized therapies. Trends include increasing demand for rare disease treatments and advancements in manufacturing technologies.
Top Tags
filing (6) · corporate-governance (6) · 10-Q (5) · financial-reporting (5) · sec-filing (4) · 8-k (4) · regulatory-filing (3) · financials (3) · executive-compensation (3) · ADMA Biologics (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenues | $371.01M | Increased from $308.91M in 2024, a 20.1% growth for the nine months ended September 30, 2025. |
| Net Income | $97.55M | Increased from $85.78M in 2024, a 13.7% growth for the nine months ended September 30, 2025. |
| Cash and Cash Equivalents | $61.39M | Decreased from $103.15M at December 31, 2024. |
| Accounts Receivable, net | $137.67M | Increased from $49.99M at December 31, 2024, a 175% increase. |
| Inventories, net | $196.67M | Increased from $170.24M at December 31, 2024. |
| Purchase of property and equipment | $21.49M | Increased from $5.47M in 2024 for the nine months ended September 30, 2025. |
| Acquisition of treasury stock | $23.04M | New activity in 2025, not present in 2024. |
| Basic Earnings Per Common Share | $0.41 | Increased from $0.37 in 2024 for the nine months ended September 30, 2025. |
| Gross Profit | $203.95M | Increased from $156.22M in 2024 for the nine months ended September 30, 2025. |
| Net cash provided by operating activities | $14.76M | Decreased from $68.46M in 2024 for the nine months ended September 30, 2025. |
| Commission File Number | 001-36728 | Identifies ADMA Biologics' registration with the SEC |
| IRS Employer Identification Number | 56-2590442 | Unique tax identification for ADMA Biologics |
| Conformed Period of Report | 20250630 | Indicates the quarter ended June 30, 2025, for this 10-Q filing |
| Filed As Of Date | 20250806 | The date the 10-Q was officially filed with the SEC |
| SEC File Number | 001-36728 | Identifies the company's filing history with the SEC. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Adma Biologics, Inc. (ADMA)?
Adma Biologics, Inc. has 44 recent SEC filings from Jan 2024 to May 2026, including 23 8-K, 6 10-Q, 6 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ADMA filings?
Across 44 filings, the sentiment breakdown is: 43 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Adma Biologics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Adma Biologics, Inc. (ADMA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Adma Biologics, Inc.?
Key financial highlights from Adma Biologics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ADMA?
The investment thesis for ADMA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Adma Biologics, Inc.?
Key executives identified across Adma Biologics, Inc.'s filings include Dr. David L. H. Chung, Mr. David M. S. Chung, Adam L. Havey, Michael A. Farrell, Maria T. Palombini, M.D..
What are the main risk factors for Adma Biologics, Inc. stock?
Of ADMA's 30 assessed filings, 0 were flagged high-risk, 9 medium-risk, and 21 low-risk.
What are recent predictions and forward guidance from Adma Biologics, Inc.?
Forward guidance and predictions for Adma Biologics, Inc. are extracted from SEC filings as they are enriched.